Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung

Huang,Chu‑Yun; Chen,Yuh‑Min; Wu,Chieh‑Hung; Tsai,Chun‑Ming; Lee,Yu‑Chin; Perng,Reury‑Perng; Whang‑Peng,Jacqueline

doi:10.3892/ol.2014.2006

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung

Authors:
- Chu‑Yun Huang
- Yuh‑Min Chen
- Chieh‑Hung Wu
- Chun‑Ming Tsai
- Yu‑Chin Lee
- Reury‑Perng Perng
- Jacqueline Whang‑Peng
View Affiliations

Affiliations: Department of Chest Medicine, Taipei Veterans General Hospital, School of Medicine, National Yang‑Ming University, Taipei 112, Taiwan, R.O.C., Centre of Excellence Cancer Research, Taipei Medical University, Taipei 112, Taiwan, R.O.C.
Published online on: March 28, 2014 https://doi.org/10.3892/ol.2014.2006
Pages: 2180-2184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Changes in circulating free DNA concentrations have been correlated with chemotherapeutic effects in solid tumors. The present study was designed to determine and compare the changes in circulating free mitochondrial DNA (mtDNA) concentrations prior to and following erlotinib treatment, as well as the potential prognostic value of plasma mtDNA. Patients with adenocarcinoma of the lung who were to receive erlotinib treatment were enrolled in the present study once informed consent had been obtained. Patient plasma samples were collected immediately prior to starting erlotinib treatment, on days 15 and 29 following the initiation of erlotinib treatment and also when the patient's disease had progressed. The most common erlotinib treatment response was a partial response (PR), achieved in 26 (49.1%) of the 53 enrolled patients, followed by stable disease (SD) in 13 patients (24.5%) and progressive disease (PD) in 14 patients (26.4%). Plasma mtDNA concentrations were significantly decreased on day 15 compared with day 0 in the patients with PD (P=0.028) or in those patients without a response to erlotinib treatment (SD and PD; P=0.007). Plasma mtDNA concentrations were similar or elevated on day 15 compared with day 0 in the patients with a PR (P=0.808). The concentration of plasma mtDNA did not correlate with progression‑free survival (PFS). Tumor epidermal growth factor receptor (EGFR) mutation status (activating mutations in 16 patients and wild‑type in 14 patients) did not correlate with the concentration of plasma mtDNA (P=0.951). Plasma mtDNA levels did not correlate with the PFS of the patients when they received erlotinib treatment. The plasma mtDNA levels were decreased on day 15 in those patients who had disease progression following erlotinib treatment. These results demonstrate that plasma mtDNA is of weak clinical utility as a screening, diagnostic or prognostic tool in lung cancer patients.

View Figures

View References

1	Wu CH, Fan WC, Chen YM, Chou KT, Shih JF, Tsai CM, et al: Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol. 5:376–379. 2010. View Article : Google Scholar : PubMed/NCBI
2	Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, et al: Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 64:92–97. 2009. View Article : Google Scholar : PubMed/NCBI
3	Pathak AK, Bhutani M, Kumar S, Mohan A and Guleria R: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 52:1833–1842. 2006.PubMed/NCBI
4	Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Koike I and Inoue T: Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci. 100:303–309. 2009. View Article : Google Scholar : PubMed/NCBI
5	Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB and Hockenbery DM: Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol. 138:449–469. 1997. View Article : Google Scholar
6	Ellinger J, Müller SC, Wernert N, von Ruecker A and Bastian PJ: Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int. 102:628–632. 2008. View Article : Google Scholar : PubMed/NCBI
7	Zhang R, Shao F, Wu X and Ying K: Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis. Lung Cancer. 69:225–231. 2010. View Article : Google Scholar : PubMed/NCBI
8	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
9	Vassilakopoulos T, Troupis T, Sotiropoulou C, Zacharatos P, Katsaounou P, Parthenis D, et al: Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer. 32:137–144. 2001. View Article : Google Scholar : PubMed/NCBI
10	Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T and Maehara Y: Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today. 34:896–901. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kulpa J, Wójcik E, Reinfuss M and Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21–1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 48:1931–1937. 2002.
12	Sozzi G, Conte D, Mariani L, et al: Analysis of circulating DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61:4675–4678. 2001.PubMed/NCBI
13	Sozzi G, Conte D, Leon M, et al: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 21:3902–3908. 2003. View Article : Google Scholar : PubMed/NCBI
14	Gai S, Fidler C, Lo YM, et al: Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer. 90:1211–1215. 2004. View Article : Google Scholar : PubMed/NCBI
15	Flamini E, Mercatali L, Nanni O, et al: Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res. 12:6985–6988. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ziegler A, Zangemeister-Wittke U and Stahel RA: Circulating DNA a new diagnostic gold mine? Cancer Treat Rev. 28:255–271. 2002. View Article : Google Scholar : PubMed/NCBI
17	Gormally E, Caboux E, Vineis P and Hainaut P: Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
18	Laktionov PP, Tamkovich SN, Rykova EY, Bryzgunova OE, Starikov AV, Kuznetsova NP, et al: Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids. 23:879–883. 2004. View Article : Google Scholar : PubMed/NCBI
19	Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P and Tsigas D: Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann NY Acad Sci. 1075:278–281. 2006. View Article : Google Scholar : PubMed/NCBI
20	Pathak AK, Bhutani M, Kumar S, Mohan A and Guleria R: Circulating free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 52:1833–1842. 2006.PubMed/NCBI
21	Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
22	Punnoose EA, Atwal S, Liu W, et al: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 18:2391–2401. 2012. View Article : Google Scholar : PubMed/NCBI
23	Penta JS, Johnson FM, Wachsman JT and Copeland WC: Mitochondrial DNA in human malignancy. Mutat Res. 488:119–133. 2001. View Article : Google Scholar : PubMed/NCBI
24	Jerónimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, et al: Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene. 20:5195–5198. 2001.PubMed/NCBI
25	Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
26	Kumar S, Guleria R, Singh V, et al: Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 36:885–892. 2010. View Article : Google Scholar : PubMed/NCBI